Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 13 Kidney Neoplasms 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 1 Recurrence 1 Neoplasms 1 Neoplasm Metastasis 1 Glioblastoma 1

Interventions

pembrolizumab 25 Cyclophosphamide 20 Nivolumab 13 Doxorubicin 13 Carboplatin 10 Surveys and Questionnaires 9 Paclitaxel 9 Exercise 9 atezolizumab 8 Vincristine 8 Rituximab 8 Radiotherapy 8 Prednisone 8 Dexamethasone 8 Bevacizumab 8 venetoclax 7 fludarabine 7 Pemetrexed 7 Fluorouracil 7 Docetaxel 7 Blood Specimen Collection 7 lenvatinib 6 dostarlimab 6 cemiplimab 6 budigalimab 6 Oxaliplatin 6 Cisplatin 6 durvalumab 5 Leucovorin 5 Lenalidomide 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Neoplasms × belzutifan × Clear all

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡